All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
Join us for the virtual Lymphoma Hub Satellite Symposium at ICML
Sequencing of therapies in high‑risk relapsed/refractory lymphoma and CLL
ICMLJune 18, 202118:00 CET
What novel targeted therapies are currently under investigation for R/R CLL?
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What novel targeted therapies are...
EMA grants marketing authorization to duvelisib monotherapy for R/R CLL or FL
On June 9, 2021, it was announced that, in May 2021, the European Medicines Agency (EMA) granted marketing authorization to single-agent duvelisib for the treatment of...
"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology."